Targeted Metabolomic Profiling of Total Fatty Acids in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry
Anas Al Aidaros,
Charu Sharma,
Claus-Dieter Langhans,
Jürgen G. Okun,
Georg F. Hoffmann,
Majed Dasouki,
Pranesh Chakraborty,
Fatma Aljasmi,
Osama Y. Al-Dirbashi
Affiliations
Anas Al Aidaros
Department of Genetics & Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain 17666, UAE
Charu Sharma
Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain 17666, UAE
Claus-Dieter Langhans
Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany
Jürgen G. Okun
Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany
Georg F. Hoffmann
Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany
Majed Dasouki
Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh 3354, Saudi Arabia
Pranesh Chakraborty
Metabolics and Newborn Screening, Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada
Fatma Aljasmi
Department of Genetics & Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain 17666, UAE
Osama Y. Al-Dirbashi
Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh 3354, Saudi Arabia
This article reports a targeted metabolomic method for total plasma fatty acids (FAs) of clinical or nutritional relevance. Thirty-six saturated, unsaturated, or branched-chain FAs with a chain length of C8-C28 were quantified using reversed-phase liquid chromatography-tandem mass spectrometry. FAs in plasma (10 μL) were acid-hydrolyzed, extracted, and derivatized with DAABD-AE (4-[2-(N,N-Dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole) at 60 °C for 1 h. Derivatization resulted in a staggering nine orders of magnitude higher sensitivity compared to underivatized analytes. FAs were measured by multiple-reaction monitoring using stable isotope internal standards. With physiological and pathological analyte levels in mind, linearity was established using spiked plasma. Intra-day (n = 15) and inter-day (n = 20) imprecisions expressed as variation coefficient were ≤10.2% with recovery ranging between 94.5–106.4%. Limits of detection and limit of quantitation ranged between 4.2–14.0 and 15.1–51.3 pmol per injection, respectively. Age-stratified reference intervals were established in four categories: 18 year. This method was assessed using samples from patients with disorders affecting FAs metabolism. For the first time, C28:0 and C28:0/C22:0 ratio were evaluated as novel disease biomarkers. This method can potentially be utilized in diagnosing patients with inborn errors of metabolism, chronic disease risk estimation, or nutritional applications.